AN2 Therapeutics, Inc. (ANTX) Price & Analysis

Compare

94 Followers

ANTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.98 - $1.68

Previous CloseN/A

Volume42.38K

Average Volume (3M)87.78K

Market Cap

$34.43M

Enterprise Value-$30.93M

Total Cash (Recent Filing)$62.92M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.01

Next Earnings

Nov 06, 2025

EPS Estimate

-0.22

Last Dividend Ex-Date

Jan 11, 2018

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.21

Shares Outstanding27,326,164

10 Day Avg. Volume72,820

30 Day Avg. Volume87,781

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.90

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.81

Forecast

1Y Price Target

$1.50

Price Target Upside26.05% Upside

Rating ConsensusModerate Sell

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

FundingCash, cash equivalents, and investments totaled $78.5M, anticipated to fund operations into 2028.

PartnershipsNow partnered with the Drugs for Neglected Diseases initiative (DNDi), AN2 can leverage DNDi’s extensive clinical trial network and expertise in Chagas disease to rapidly advance the Phase 2 planning for AN2-502998.

Regulatory OutlookThe FDA is likely to accept Quality of Life measures as an efficacy endpoint, which is beneficial for the drug's approval process.

Bears Say

Clinical TrialsThe final shoe has dropped for AN2 Therapeutics' epetraborole program in refractory MAC lung disease, as the EBO-301 Ph.3 study missed the primary endpoint.

Efficacy ResultsThe culture conversion results for epetraborole were disappointing, although not unexpected.

Study OutcomesUnfortunately, the truncated EBO-301 Ph.3 study missed the primary endpoint and was unable to confirm the clinical efficacy observed in the Ph.2 portion.

AN2 Therapeutics, Inc. News

AN2 Therapeutics reports Q2 EPS (21c) vs. (48c) last year

“We saw continued momentum this quarter across our boron chemistry pipeline as we look to develop high-impact drugs...

28d ago

ANTX

AN2 Therapeutics completes dosing in cohort in AN2-502998 trial

AN2 Therapeutics (ANTX) announced that it has completed dosing the first single ascending dose cohort in its Phase...

29d ago

ANTX

AN2 Therapeutics, Inc.: Hold Rating Amid Early-Stage Progress and Financial Uncertainty

AN2 Therapeutics, Inc., the Healthcare sector company, was revisited by a Wall Street analyst on August 13. Analyst...

26d ago

ANTX

AN2 Therapeutics Reports Improved Financial Results

AN2 Therapeutics, Inc. ( ($ANTX) ) has released its Q2 earnings. Here is a breakdown of the information...

28d ago

ANTX

AN2 Therapeutics, DNDi collaborate on development of AN2-502998

AN2 Therapeutics (ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative announced a collaboration to...

2M ago

ANTX

AN2 Therapeutics completes 200-patient observational study in acute melioidosis

AN2 Therapeutics (ANTX) announced the completion of a 200-patient observational study in acute melioidosis, a highly lethal bacterial...

2M ago

ANTX

AN2 Therapeutics Enhances Financial Flexibility with Share Exchange

AN2 Therapeutics, Inc. ( ($ANTX) ) has issued an update. On June 17 and June 19, 2025, AN2...

3M ago

ANTX

AN2 Therapeutics Unveils Updated Investor Presentation

AN2 Therapeutics, Inc. ( ($ANTX) ) just unveiled an announcement. On June 11, 2025, AN2 Therapeutics, Inc. released...

3M ago

ANTX

AN2 Therapeutics Elects New Directors at Annual Meeting

AN2 Therapeutics, Inc. ( ($ANTX) ) has shared an announcement. On May 22, 2025, AN2 Therapeutics, Inc. held...

4M ago

ANTX

AN2 Therapeutics, Inc.: Hold Rating Amid Strategic Shift and Financial Resilience

In a report released on May 13, Joseph Schwartz from Leerink Partners maintained a Hold rating on AN2...

4M ago

ANTX

AN2 Therapeutics reports Q1 EPS (35c) vs. (56c) last year

The Company had cash, cash equivalents and investments of $78.5 million at March 31, 2025. The Company projects...

4M ago

ANTX

AN2 Therapeutics price target lowered to $2 from $5 at Citizens JMP

Citizens JMP analyst Roy Buchanan lowered the firm’s price target on AN2 Therapeutics (ANTX) to $2 from $5...

4M ago

ANTX

AN2 Therapeutics Faces Setback in Phase 3 Study

AN2 Therapeutics, Inc. ( ($ANTX) ) has issued an update. AN2 Therapeutics announced the results of the Phase...

4M ago

ANTX

AN2 Therapeutics reports data fro previously terminated EBO-301 Study

AN2 Therapeutics (ANTX) “announced topline results from the Phase 3 portion of the EBO-301 study evaluating epetraborole on...

4M ago

ANTX

ANTX FAQ

What was AN2 Therapeutics, Inc.’s price range in the past 12 months?

AN2 Therapeutics, Inc. lowest stock price was $0.97 and its highest was $1.68 in the past 12 months.

What is AN2 Therapeutics, Inc.’s market cap?

AN2 Therapeutics, Inc.’s market cap is $34.43M.

When is AN2 Therapeutics, Inc.’s upcoming earnings report date?

AN2 Therapeutics, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 57 days.

How were AN2 Therapeutics, Inc.’s earnings last quarter?

AN2 Therapeutics, Inc. released its earnings results on Aug 12, 2025. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.125.

Is AN2 Therapeutics, Inc. overvalued?

According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AN2 Therapeutics, Inc. pay dividends?

AN2 Therapeutics, Inc. pays a Quarterly dividend of $0.656 which represents an annual dividend yield of N/A. See more information on AN2 Therapeutics, Inc. dividends here

What is AN2 Therapeutics, Inc.’s EPS estimate?

AN2 Therapeutics, Inc.’s EPS estimate is -0.22.

How many shares outstanding does AN2 Therapeutics, Inc. have?

AN2 Therapeutics, Inc. has 27,326,164 shares outstanding.

What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?

AN2 Therapeutics, Inc. reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ANTX

AN2 Therapeutics, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-44.71%

Trailing 12-Months

Asset Growth

-30.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. (ANTX) is a biopharmaceutical company focused on developing novel treatments for rare, chronic, and serious infectious diseases. The company operates within the healthcare and biotechnology sectors, leveraging advanced scientific research to address unmet medical needs. AN2 Therapeutics is primarily engaged in the research, development, and commercialization of therapeutic products, particularly targeting conditions that lack effective treatment options.

AN2 Therapeutics, Inc. (ANTX) Earnings & Revenues

Historic Earnings Reports

ANTX Stock 12 Month Forecast

Average Price Target

$1.50

▲(26.05% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","2":"$2","3":"$3","4":"$4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.1323076923076925,1.2046153846153846,1.276923076923077,1.3492307692307692,1.4215384615384616,1.493846153846154,1.5661538461538462,1.6384615384615384,1.7107692307692308,1.7830769230769232,1.8553846153846154,1.9276923076923078,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.093846153846154,1.1276923076923078,1.1615384615384616,1.1953846153846155,1.2292307692307693,1.2630769230769232,1.2969230769230768,1.330769230769231,1.3646153846153846,1.3984615384615386,1.4323076923076923,1.4661538461538461,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.06,1.0553846153846154,1.050769230769231,1.0461538461538462,1.0415384615384615,1.036923076923077,1.0323076923076924,1.0276923076923077,1.023076923076923,1.0184615384615385,1.0138461538461538,1.0092307692307692,1.0046153846153847,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.76,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >